Our results support the hypothesis that individuals with detectable RA autoantibodies, but no clinically evident disease represent an intermediate phenotype exhibiting some of the immunological features seen in the circulating CD4+ T lymphocytes of patients with established RA, particularly an increased expression of the immune checkpoint receptor TIGIT, primarily among PD-1+ cell subsets. This evidence concerns the gene TIGIT and rheumatoid arthritis.